MedTrace Logo

Endostar Treatment of Advanced Non-small Cell Lung Cancer Multi-center Clinical Research

NCT02513355 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2015-08-04

No results posted yet for this study

Summary

Research purpose:

Degree of continuous intravenous pumping Endostar (human recombinant endostatin) combination chemotherapy regimens including cisplatin two medicine first-line treatment of advanced non-small cell lung cancer (with the exception of EGFR/ALK mutations) efficacy and safety.

Conditions

Interventions

BIOLOGICAL

Endostar

Endostar 15mg/m2, 21 days per cycle, 4 to 6 cycles

DRUG

Changchun marina

25mg/m2,d1 and d8,q21d×4

DRUG

cisplatin

80mg/m2,d1, q21d×4

DRUG

Taxol

135-175mg/m2,d1,q21d×4

DRUG

parapl

AUC=5-6,d1,q21d×4

Sponsors & Collaborators

  • Nanjing NingQi Medicine Science and Technology Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Han gaohua, PI · China:Taizhou people's hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2017-11-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02513355 on ClinicalTrials.gov